Boundless Bio, Inc. (BOLD)
NASDAQ: BOLD · IEX Real-Time Price · USD
3.560
-0.320 (-8.25%)
At close: Jul 19, 2024, 4:00 PM
3.390
-0.170 (-4.78%)
Pre-market: Jul 22, 2024, 8:12 AM EDT
Boundless Bio Employees
Boundless Bio had 72 employees as of December 31, 2023.
Employees
72
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$738,125
Market Cap
79.23M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 72 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Marinus Pharmaceuticals | 166 |
| Affimed | 76 |
| PMV Pharmaceuticals | 63 |
| Leap Therapeutics | 54 |
| Milestone Pharmaceuticals | 47 |
| Ikena Oncology | 43 |
| Forian | 37 |
| SCYNEXIS | 29 |
BOLD News
- 6 weeks ago - Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 2 months ago - Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights - Business Wire
- 2 months ago - Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 - Business Wire
- 3 months ago - Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications - Business Wire
- 3 months ago - Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 - Business Wire
- 4 months ago - Boundless Bio Announces Pricing of Initial Public Offering - Business Wire
- 4 months ago - Oncology biotech Boundless Bio files for a $100 million IPO - Renaissance Capital
- 4 months ago - Boundless Bio Eyes Nasdaq: Unveiling Cancer Therapy Innovation and IPO Ambitions - BNN